Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionVictory Capital Management Inc
Latest Disclosed Ownership195,937 shares
Latest Disclosed Value $ 64,829,675
Victory Capital Management Inc reports 11.29% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Victory Capital Management Inc filed a 13F-HR form disclosing ownership of 195,937 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $55,979,201 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 220,866 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -11.29% during the quarter. The current value of the position is $51,041,588 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 195,937 -24,929 -11.29 64,830 -26.19 0.0311
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 220,866 40,517 22.47 87,827 6.79 0.0496
2025-11-12 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 180,349 24,055 15.39 82,239 61.34 0.0481
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 156,294 118,645 315.13 50,971 401.44 0.0329
2025-05-02 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 37,649 -2,148 -5.40 10,166 8.55 0.0104
2025-02-06 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 39,797 -3,112 -7.25 9,365 -20.65 0.0092
2024-11-05 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,909 4,229 10.93 11,801 25.56 0.0114
2024-08-05 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 38,680 -724 -1.84 9,399 59.63 0.0094
2024-05-03 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 39,404 -6,334 -13.85 5,889 -32.74 0.0057
2024-02-05 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,738 -13,149 -22.33 8,755 -16.05 0.0092
2023-11-06 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 58,887 -1,606 -2.65 10,429 -9.24 0.0120
2023-07-27 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,493 -377 -0.62 11,490 -5.77 0.0126
2023-05-02 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,870 738 1.23 12,193 -14.67 0.0137
2023-04-25 2022-12-31 13F/A-3 ALNYLAM PHARMACEUTICALS COM 02043Q107 60,132 1,045 1.77 14,290 20.83 0.0164
2023-03-10 2022-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 60,132 1,045 14,290 0.0156
2023-02-10 2022-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 60,132 1,045 14,290 0.0000
2023-02-09 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,507 1,420 13,699 0.0093
2022-11-02 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 59,087 7,822 15.26 11,827 58.18 0.0138
2022-08-01 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,265 -220 -0.43 7,477 8.84 0.0085
2022-05-04 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,485 -4,877 -8.65 6,870 -28.12 0.0069
2022-02-07 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 56,362 484 0.87 9,558 -9.40 0.0088
2021-11-02 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,878 14,756 35.88 10,550 51.34 0.0103
2021-08-03 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,122 -16,922 -29.15 6,971 -14.94 0.0067
2021-05-04 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 58,044 7,080 13.89 8,195 23.72 0.0084
2021-02-01 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 50,964 6,151 13.73 6,624 1.52 0.0074
2020-11-09 2020-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 44,813 6,726 17.66 6,525 15.67 0.0084
2020-08-07 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 38,087 -2,930 -7.14 5,641 26.34 0.0076
2020-05-12 2020-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 41,017 24,544 149.00 4,465 135.37 0.0075
2020-05-04 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,017 24,544 4,465 4,886.4888
2020-02-06 2019-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 16,473 1,127 7.34 1,897 53.73 0.0023
2020-02-04 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,421 -925 1,655 1,983.8330
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,346 15,346 1,234 0.0016
2018-08-02 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -15,555 -100.00 0 -100.00
2018-05-04 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,555 -4,380 -21.97 1,853 -26.85 0.0040
2018-02-01 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,935 -3,240 -13.98 2,533 -6.98 0.0053
2017-10-27 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,175 -2,850 -10.95 2,723 31.17 0.0061
2017-08-07 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,025 1,210 4.88 2,076 63.21 0.0049
2017-05-10 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,815 4,725 23.52 1,272 69.15 0.0030
2017-02-09 2016-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 20,090 20,090 752 0.0019
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.